Real Facts Involving The VE-821 Successes

A multivariate logistic regression analysis was then performed using as independent variables those that were statistically significant in the univariate model as well as those with a plausible potential biological association (adjusted model). Odds ratios (OR) with the appropriate two-sided 95% confidence intervals (CI) were reported. All tests were two sided, and P Azastene of CKDa A large proportion of individuals (66%) were on PPIs, and all participants Pictilisib mw were receiving phosphate binders. More than 50% of them were using sevelamer carbonate, while the remaining were on calcium acetate (32%) or calcium carbonate (13%). None of them received aluminum or iron-containing phosphate binders. Serum magnesium concentrations were significantly higher in those individuals receiving sevelamer compared with those who did not (2.05 �� 0.3 versus 1.8 �� 0.4 mg/dL, respectively; P = 0.0064) (Figure?1). Fig.?1. Mean serum magnesium (mg/L) in patients with and without sevelamer (P VE-821 clinical trial of different variables and their relationship with the presence or absence of hypomagnesemia In the multivariate model including the use of PPIs, sevelamer carbonate resulted in an independent protective factor for hypomagnesemia (OR: 0.44; 95% CI: 0.21�C0.87) (Table?4). Table?4. Adjusted multivariate model for the risk of developing hypomagnesemia Discussion Our study shows that patients using sevelamer carbonate as phosphate binder in dialysis have a lower risk of hypomagnesemia, even after correcting for the use of PPIs. Sevelamer carbonate, a calcium-free intestinally non-absorbed polymer, is approved for hyperphosphatemic dialysis patients in the USA and hyperphosphatemic stage 3�C5 CKD patients in many other countries.